Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-01-13
1996-05-21
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514466, 514824, A61K 3142, A61K 3136
Patent
active
055190421
ABSTRACT:
A method of preventing or treating hyperproliferative vascular disease in a mammal consists of administering to a mammal an effective amount of carboxyamide compounds.
REFERENCES:
patent: 4061767 (1977-12-01), Ertel et al.
The Merck Index, 10th Edition, p. 396, abstract No. 2748. (1983).
Herrman et al., Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty. The Search for the Holy Grail? (Part II): Drugs; 1993; (Abstract).
Grinstead et al.; Amiprilose in the Prevention of Restenosis After Coronary Intervention in a Swine Model; Coron. Artery Dis.; 1993 (Abstract).
Stone et al.; A Randomized Trial of Corticosteroids for the Prevention of Restenosis in 102 Patients Undergoing Repeat Coronary Agioplasty; Catheter. Cardiovasc. Diagn.; 1989 (Abstract).
Pepine et al.; A Controlled Trial of Cortiscosteroids to Prevent Restenosis After Coronary Angioplasty; Circulation; 1990 (Abstract).
Muller et al.; Site-Specific Dexamethasone Delivery for the Prevention of Neointimal Thickening After Vascular Stent Implantation; Coron. Artery Dis.; 1994 (Abstract).
Karas et al.; Restenosis Following Coronary Angioplasty; Clin. Cardiol.; 1991 (Abstract).
MacDonald et al., Effects of Leflunomide and Cyclosporine on Aortic Allograft Chronic Rejection in the Rat, Transplantation Proceedings, vol. 26, No. 6, pp. 3244-3245 (Dec. 1994).
Mattar et al., Inhbition of the Epidermal Growth Factor Receptor Tyrosine Kinase Activity by Leflunomide, FEBS 13234, vol. 334, No. 2, pp. 161-164 (Nov. 1993).
Williams et al., Immunosuppressive Effects of Leflunomide in a Cardiac Allograft Model, Transplantation Proceedings, vol. 25, No. 1, pp. 745-746 (Feb. 1993).
Bartlett et al., Leflunomide (HWA 486), A Novel Immunomodulating Compound For The Treatment of Autoimmmune Disorders and Reactions Leading to Transplantation Rejection, Agents and Actions, vol. 32, 1/2, pp. 10-21 (1991).
Bilder et al., Tyrphostins Inhibit PDGF-Induced DNA Synthesis and Associated Early Events in Smooth Muscle Cells, American Journal of Physiology, vol. 260, No. 4, pp. C721-C730, (Apr. 1991).
Cao et al., Leflunomide, A New Immunosuppressant, Inhibits Trosine Kinase, Calcium Signaling and DNA Sythesis in Vascular Smooth Muscle Cells, The FASEB Journal, Transplantation: Tolerance and Rejection 2812, vol. 8, No. 4, (Mar. 1994).
Foegh et al., Molecular Biology of Intimal Proliferation, Current Opinion in Cardiology, vol. 8, No. 6 pp. 938-950, (Nov. 1993).
Gregory et al., Leflunomide is a New Immunosuppresant that Effectively Reduced Arterial Intimal Thickening Produced by Alloimmune Injury, The Journal of Heart and Lung Transplantation, vol. 13, No. 1, Part. 2, p. S68, Abstract No. 145, (Jan./Feb. 1994).
Bartlett Robert R.
Morris Randall E.
Cintins Marianne M.
Hoechst Aktiengesellschaft
Weddington Kevin E.
LandOfFree
Method of treating hyperproliferative vascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating hyperproliferative vascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating hyperproliferative vascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2038364